Celltrion said on the 2nd that it launched the subcutaneous infliximab formulation Remsima SC in Chile, the first entry into the Latin American public market.
The company's Chile subsidiary held supply talks with the local National Health Supply Center (CENABAST) for Remsima SC and recently completed delivery of the first batch, formally beginning sales, it said.
Celltrion obtained marketing approval for Remsima SC from the Chile Public Health Institute (ISP) in Apr. 2023 and has since been engaging with the government with the goal of securing inclusion in public insurance.
In Latin America, pharmaceutical supply channels are split between the public and private markets at an 8-to-2 ratio, effectively making the public market the core of product sales.
Celltrion plans to gradually expand the regions where Remsima SC is sold, starting with this supply in Chile.